Drug intelligence / Profile preview

cambritaxestat

Development stage: Phase 2
Lead developer: iOnctura
Modality: Small Molecules
Administration: Oral

Overview

Cambritaxestat is an autotaxin inhibitor developed for the treatment of cancer, particularly metastatic pancreatic cancer. It inhibits both the catalytic and chaperone activities of the autotaxin enzyme, which is involved in the production of lysophosphatidic acid (LPA), a bioactive phospholipid implicated in cancer progression. Cambritaxestat is being developed by iOnctura as a first-in-class therapy for highly fibrotic tumors. It is orally dosed and has shown preclinical efficacy in reducing metastasis and tumor outgrowth. The drug is currently in Phase I/II clinical trials for pancreatic cancer.

Other names: CRT0273750CRT-0273750CRT 0273750CHEMBL3917975CHEMBL-3917975CHEMBL 3917975

Targets

ENPP2 (Ectonucleotide pyrophosphatase/phosphodiesterase family member 2)

Beyond the preview

Go deeper on cambritaxestat.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cambritaxestat.

Explore the full profile